reports
Form 8.3 - Mattioli Woods
Form 8.3 - Mattioli Woods 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: ...
Hanjin Transportation Co: 1 director
A director at Hanjin Transportation Co bought 2,000 shares at 21,350.000KRW and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Ocean Power Technologies Announces Teaming Agreement with Major Intern...
Ocean Power Technologies Announces Teaming Agreement with Major International Defense Contractor to Deploy Maritime Domain Awareness Solutions MONROE TOWNSHIP, N.J., April 16, 2024 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT” or the “Company”), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced it has signed a teaming agreement with a major international defense contractor to provide its Merrows suite of solutions with a focus on certain geographic regions. This alliance is set to advance marit...
APT Medical Inc: 1 director
A director at APT Medical Inc sold 188,695 shares at 471.120CNY and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
SMC Trading Investment JSC: 1 director
A director at SMC Trading Investment JSC sold 9,581,821 shares at 0.000VND and the significance rating of the trade was 90/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
CIC39 Corporation: 1 director
A director at CIC39 Corporation maiden bought 101,600 shares at 0.000VND and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
More Acquisitions on Horizon for Ladybug’s Growing E-Commerce Revenue ...
More Acquisitions on Horizon for Ladybug’s Growing E-Commerce Revenue Model TULSA, Okla., April 16, 2024 (GLOBE NEWSWIRE) -- In Tulsa, Oklahoma, on April 16, 2024, Ladybug Resource Group, Inc. (OTC PINK: LBRG) announced that the company is making strategic moves in the e-commerce space, with its subsidiary Growhouse Nutraceuticals Ltd., eyeing the acquisition of ‘Your Supplement Supply Store Ltd.'s’ primary website. This acquisition aims to bolster Ladybug's online footprint and is projected to generate an additional $2.25 million in annual revenue. Growhouse's focus on acquiring uniqu...
XWELL, Inc. to Report Fiscal Year 2023 Financial Results on Tuesday, A...
XWELL, Inc. to Report Fiscal Year 2023 Financial Results on Tuesday, April 16, 2024 Webcast and Conference Call Scheduled for 5:00 PM ET NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today announced that it will report results for the year ended December 31, 2023, on Tuesday, April 16, 2024, after the market close. The announcement will be followed by a webcast and conference call at 5:00 p.m. ET. The Company encourages investors, and interested parties, to listen via webcast ...
Solid Power Announces Upcoming Investor Conference Schedule
Solid Power Announces Upcoming Investor Conference Schedule LOUISVILLE, Colo., April 16, 2024 (GLOBE NEWSWIRE) -- , Inc. ("Solid Power") (Nasdaq: ), a leading developer of solid-state battery technology, today announced it will participate in the following investor conferences in the coming months: Janney Fireside ChatPresentation date and time: April 17, 2024, 2:00pm ETLocation: Virtual Oppenheimer 9th Annual Emerging Growth ConferenceDate: May 9, 2024Location: Virtual JP Morgan Virtual Battery SeriesPresentation date and time: May 15, 2024, 10:00am ETLocation: Virtual TD Cowen’s 2nd...
Franklin Electric Schedules Its First Quarter 2024 Earnings Release an...
Franklin Electric Schedules Its First Quarter 2024 Earnings Release and Conference Call FORT WAYNE, Ind., April 16, 2024 (GLOBE NEWSWIRE) -- Franklin Electric Co., Inc. (NASDAQ: FELE) will release its first quarter 2024 earnings at 8:00 am ET on Tuesday, April 30, 2024. A conference call to review earnings and other developments in the business will commence at 9:00 am ET. The first quarter 2024 earnings call will be available via a live webcast. The webcast will be available in a listen only mode by going to: For those interested in participating in the question-and-answer portion of ...
Xtep International Holdings Ltd: 1 director
A director at Xtep International Holdings Ltd bought 1,457,500 shares at 4.445HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Money via WhatsApp: Intermex & Félix Pago Make It Effortless
Money via WhatsApp: Intermex & Félix Pago Make It Effortless MIAMI, April 16, 2024 (GLOBE NEWSWIRE) -- In an innovative step towards reshaping the landscape of money transfer to Latin America, Intermex, a leading omnichannel money transfer service provider, has announced its strategic partnership with Félix Pago. The Félix Pago partnership with Intermex, creates a user-friendly chat-based platform, aimed at facilitating money transfers for Latin American families in the US to their loved ones back home. This alignment between Félix Pago and Intermex marks a new era in money transfers, ...
GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the company’s latest milestones along with our clinical adoption of the Company’s groundbreaking geneType Risk Assessment Tests routinely across 12 states in the United States and nationally in Australia. The geneType team has achieved clinical proof of concept in key markets including ge...
Westpac NZ Wins FICO Award After Successfully Adopting Platform and En...
SAN DIEGO--(BUSINESS WIRE)-- FICO World – FICO (NYSE: FICO) Highlights: Westpac NZ wins the 2024 FICO® Decisions Pioneer Award Westpac NZ increases customer engagement and process automation with FICO® Platform Partnership with FICO delivers greater agility and data-driven collections improvements Today at FICO® World, the industry’s leading analytic and AI event, has won the 2024 FICO® Decisions Pioneer Award, for using the industry-leading capabilities of to advance hyper-personalization and accelerate digital service innovation. The bank’s partnership with FICO has resulte...
STMicroelectronics Publishes 2024 Sustainability Report
STMicroelectronics Publishes 2024 Sustainability Report STMicroelectronics Publishes 2024 Sustainability Report On track to become carbon neutral on scope 1 and 2, and partially scope 3, by 2027 with global sourcing of electricity from renewable energy growing to 71% in 2023, from 62% in 202287% of employees would recommend ST as a great place to work12.2% of net revenues (US$2.1 billion) invested in R&D to support innovation Geneva, Switzerland, April 16, 2024 - STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications...
STMicroelectronics publie l’édition 2024 de son rapport Développement ...
STMicroelectronics publie l’édition 2024 de son rapport Développement Durable STMicroelectronics publie l’édition 2024 de son rapport Développement Durable ST est en bonne voie pour atteindre la neutralité carbone pour les scopes 1 et 2, ainsi qu’une partie du scope 3, d’ici 2027 y compris l'approvisionnement mondial en électricité provenant d’énergie renouvelable atteignant 71 % en 2023 au lieu de 62 % en 2022. 87 % des employés recommanderaient ST comme une entreprise où il fait bon travailler.ST a investi 12,2 % de son chiffre d’affaires net (soit 2,1 milliards de dollars US) en R&D en...
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Stud...
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a checkpoint blocker. CTX-8371 is a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1.Compass advanced CTX-8371 to the clinic following pre-clinical observations of superior activity when compared with approved checkpoint ...
Asset Entities Announces Filing of S-3 Shelf Registration Statement
Asset Entities Announces Filing of S-3 Shelf Registration Statement DALLAS, April 16, 2024 (GLOBE NEWSWIRE) -- Asset Entities Inc. (“Asset Entities” or “the Company”) (NASDAQ: ASST), a provider of digital marketing and content delivery services across Discord and other social media platforms, and Ternary Payment Platform company, which just over a year ago became the first sub-Discord technology company to go public on Nasdaq, announces that it has filed a Form S-3 shelf registration statement (the “S-3”) with the U.S. Securities and Exchange Commission (“SEC”). Once the registration s...
NV5 to Host First Quarter 2024 Conference Call on Wednesday, May 8th a...
NV5 to Host First Quarter 2024 Conference Call on Wednesday, May 8th at 4:30pm ET HOLLYWOOD, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of technology, conformity assessment, and consulting solutions, will announce its financial results for the first quarter ended March 30, 2024, on Wednesday, May 8, 2024, following the close of the markets. The Company will host an earnings conference call at 4:30 p.m. Eastern time the same day. NV5 Executive Chairman, Dickerson Wright, and Chief Financial Officer, Edward Codispoti, will ...
Charles River Laboratories Launches Alternative Methods Advancement Pr...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing. The initiative aims to drive the new standard for drug discovery and development and encapsulates the Company’s initial $200 million investment over the past four years and its five-year goal of investing an additional $300 million. This investment spans a portfolio of technology innovations, partnerships, and advocacy efforts to reduce...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.